Filing Details

Accession Number:
0001628280-23-036755
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-11-03 16:39:14
Reporting Period:
2023-11-01
Accepted Time:
2023-11-03 16:39:14
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1501697 X4 Pharmaceuticals Inc XFOR Biological Products, (No Disgnostic Substances) (2836) 273181608
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1830901 Arthur Taveras C/O X4 Pharmaceuticals, Inc.
61 North Beacon Street 4Th Floor
Boston MA 02134
Chief Scientific Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2023-11-01 67,695 $0.73 249,323 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Footnotes
  1. These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 24, 2023.
  2. Sale of shares to cover personal income tax obligation upon settlement of restricted stock unit award
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.6841 to $0.80, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.